Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Rheumatoid Arthritis

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Ann Rheum Dis.

Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB

doi: 10.1136/annrheumdis-

Rheumatoid Arthritis

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis

Rheumatology (Oxford).

Silva-Fernández L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.

doi: 10.1093/

Rheumatoid Arthritis

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register

Rheumatology (Oxford).

Bechman K, Oke A, Yates M, Norton S, Dennison E, Cope AP, Galloway JB

doi: 10.1093/rheumatology/kez671.

Rheumatoid Arthritis

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register

BMC Musculoskelet Disord.

McWilliams DF, Walsh DA

doi: 10.1186/s12891-016-1192-7.

Rheumatoid Arthritis

The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register

Arthritis Rheumatol.

Gwinnutt JM, Symmons DP, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SM

doi: 10.1002/art.40090.

Psoriatic Arthritis

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Rheumatology (Oxford)

Tillett W, Allen A, Tucker L, Chandler D, Ciurtin C, Davis C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Coates LC

doi: 10.1093/rheumatology/keaa526

Rheumatoid Arthritis

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response

Ann Rheum Dis.

Cherlin S, Lewis MJ, Plant D, Nair N, Goldmann K, Tzanis E, Barnes MR, McKeigue P, Barrett JH, Pitzalis C, Barton A, MATURA Consortium., Cordell HJ

doi: 10.1136/annrheumdis-2020-217204.

Further Publications Rheumatology

Prevalence and predictors of adverse events with methotrexate mono- and combination- therapy for rheumatoid arthritis: a systematic review

Rheumatology (Oxford)

Sherbini AA, Sharma SD, Gwinnutt JM, Hyrich KL, Verstappen SMM

doi: 10.1093/rheumatology/keab304

COMMENTED

Rheumatoid Arthritis

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

★ 3 Recommended and commented by Dr Heino Prillwitz, Faculty Member

doi: 10.1186/s13075-019-2059-8.

Related content

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register

The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register

Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response

Prevalence and predictors of adverse events with methotrexate mono- and combination- therapy for rheumatoid arthritis: a systematic review

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs